Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lim ZY et al. – In MDS or AML patients with advanced disease receiving alemtuzumab–based RIC HSCT, the HCT–CI provides an important means of stratifying patients with a high risk of inferior transplant outcomes.



Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address